Search Results for "Pirfenidone Neurofibromatosis"
Original Source: Pirfenidone in Treating Young Patients With Neurofibromatosis Type 1 and Plexiform Neurofibromas
RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. Pirfenidone may slow the growth or prevent further development of plexiform neurofibromas. PURPOSE: Phase I trial to study the effectiveness of pirfenidone in treating young patients who have neurofibromatosis type 1 and plexiform neurofibroma.
Matching Channels
None
Matching News
Danish sperm donor passed neurofibromatosis on to five children
Danish health authorities are expected to restrict regulations regarding sperm donation after a donor was found to have passed on the genetic disease neurofibromatosis to at least five children he......
HRI to begin enrollment in RAD001 Phase II trial for Neurofibromatosis Type-2
House Research Institute (HRI) is recruiting patients for a Phase II clinical trial to test a medication that may slow the progression of Neurofibromatosis Type-2, commonly referred to as NF2.
GNI looks to begin Chinese trials with pirfenidone for diabetic nephropathy
The wholly owned Shanghai Genomics subsidiary of the Japan-based venture GNI has applied to begin the clinical development in China of its lead product, pirfenidone, for the additional indication of d...
Researchers identify therapeutic targets in neurofibromatosis
(Journal of Clinical Investigation) In this issue of the Journal of Clinical Investigation, three independent groups of researchers report that MAPK hyperactivation is a critical mediator of disease p...
Pirfenidone approved by NICE for pulmonary fibrosis
Pirfenidone (Esbriet) can now be prescribed on the NHS for some patients with idiopathic pulmonary fibrosis in England and Wales, according to new guidance from the National Institute for Health and...
Neurofibromatosis-1 may increase risk of breast cancer in women
New Johns Hopkins research showing a more than four-fold increase in the incidence of breast cancer in women with neurofibromatosis-1 (NF1) adds to growing evidence that women with this rare genetic d...
Potential Non-Surgical Therapy For Neurofibromatosis Type 2 Brain Tumors
One in 25,000 people worldwide is affected by neurofibromatosis type 2 (NF2), a condition where the loss of a tumour suppressor called Merlin results in multiple tumours in the brain and nervous syste...
Learning Disabilities In Kids May Be Preventable With Cancer Drug
According to a new study conducted by researchers at University of Michigan Medical School and published in the journal Cell, a drug which was originally formulated to stop cancer growth may be capabl...
Matching PubMed Articles
Pirfenidone suppresses keloid fibroblast-embedded collagen gel contraction.
Keloid is a clinically intractable disease that causes disfigurement, itching, and pain due to abnormal proliferation of fibroblasts and production of collagen. Pirfenidone is a novel anti-fibrotic ag...
Polarized T helper type 2 (Th2) response is linked with fibrosis. Here, we evaluated the effect of the anti-fibrotic agent pirfenidone on Th type 1 (Th1) and Th2 responses. For in vivo testing; Wistar...
ABSTRACT: BACKGROUND: Our phase III clinical trial of pirfenidone for patients with idiopathic pulmonary fibrosis (IPF) revealed the efficacy in reducing the decline of vital capacity (VC) and increas...
Emerging potential treatments: new hope for idiopathic pulmonary fibrosis patients?
Currently, there are no approved pharmacological treatments for the management of patients with idiopathic pulmonary fibrosis (IPF) in the USA or Europe. Pirfenidone is an orally bio-available small m...
Pirfenidone: in idiopathic pulmonary fibrosis.
Pirfenidone is an orally administered pyridine that has orphan designation for the treatment of mild to moderate idiopathic pulmonary fibrosis (IPF) in the EU. Pirfenidone 2403 mg/day for 72 weeks a...
